


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A compound of formula I



in salt or zwitterionic form wherein

R^1 and R^3 are each independently a C3-C15-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R^2 is hydrogen, hydroxy, or C1-C4-alkyl optionally substituted by hydroxy;

J is C1-C2-alkylene;

R^4 is C1-C4-alkyl;

R^5 is C1-alkyl substituted by $-\text{CO}-R^6$, or $-\text{CO}-\text{NH}-R^6$,

or R^5 is C2-C10-alkyl substituted by $-\text{O}-R^6$, $-\text{O}-\text{CO}-R^6$, or $-R^8$,

or R^5 is C2-C10-alkenyl or C2-C10-alkynyl optionally substituted by $-R^8$;

R^6 is a C3-C15-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur,

or R^6 is C1-C10-alkyl optionally substituted by C1-C10-alkoxy, $-\text{O}-R^8$ or a C3-C15-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur; and

R^8 is a C3-C15-carbocyclic group.

Claim 2. (Canceled)

Claim 3. (Currently Amended) A compound according to claim 3 elaim-2, wherein

R^1 and R^3 are each independently a C3-C10-carbocyclic group, preferably phenyl, or a 5- to 9-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur, preferably thienyl;

R^2 is hydroxy;

J is C1-C2-alkylene;

R^4 is C1-C4-alkyl;


R^5 is C1-alkyl substituted by $-\text{CO}-R^6$ or $-\text{CO}-\text{NH}-R^6$,

or R^5 is C2-C5-alkyl substituted by $-\text{O}-R^6$, $-\text{O}-\text{CO}-R^6$ or $-R^8$,

or R^5 is C2-C4-alkenyl or C2-C8-alkynyl optionally substituted by $-R^8$;
 R^6 is a C3-C10-carbocyclic group, preferably phenyl,
 or R^6 is C1-C15-alkyl optionally substituted by C1-C4-alkoxy, $O-R^8$ or a C3-C10-carbocyclic group; and
 R^8 is a C3-C10-carbocyclic group, preferably phenyl.


Claims 4-7. (Canceled)


Claim 8. (Previously Presented): A compound according to claim 1, which is also a compound of formula XVI




where T is as shown in the following table:


T










Claim 9. (Previously Presented): A compound according to claim 1, which is also a compound of formula XVII



where T is as shown in the following table:








Claim 10. (Cancelled)

Claim 11. (Previously Presented): A pharmaceutical composition comprising as active ingredient a compound according to claim 1.

Claims 12-15. (Cancelled)

Claim 16. (Currently Amended): A process for the preparation of a compound of formula I as claimed in claim 1 which comprises:

(i) (A) reacting a compound of formula II




or a protected form thereof where R^1 , R^2 , R^3 , R^4 , and J, are as defined in claim 1, with a compound of formula III



where R^5 is as defined in claim 1 and X is chloro, bromo or iodo;

(B) reacting a compound of formula IV




or a protected form thereof where R^1 , R^2 , R^3 , R^5 , and J, L and M are as defined in claim 1, with a compound of formula V



where R^4 is as defined in claim 1 and X is chloro, bromo or iodo; and

(ii) recovering the product in salt or zwitterionic form.

Claim 17. (Currently Amended): A compound of formula VI



in salt or zwitterionic form wherein

R¹ and R³ are each independently a C₃-C₁₅-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R² is hydrogen, hydroxy, or C₁-C₄-alkyl optionally substituted by hydroxy;

J is C₁-C₂-alkylene;

R⁴ is C₁-C₄-alkyl; and

Q is C₁-C₁₀-alkylene.

Claim 18. (Original): A pharmaceutical composition according to claim 11 wherein the compound is a single enantiomer.

Claim 19. (Canceled)

Claim 20. (Withdrawn - Original): A method of treating a condition mediated by the muscarinic M₃ receptor in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I as defined in claim 1 in free form or in the form of a pharmaceutically acceptable salt.

Claim 21. (Withdrawn - Original): A method of treating an inflammatory or obstructive airways disease in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I as defined in claim 1 in free form or in the form of a pharmaceutically acceptable salt.

Claim 22. (Withdrawn - Original): A method according to claim 20, in which the compound of formula I is a single enantiomer.